Acute cardiac care & resuscitation
Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial
Authors' conclusion
No treatment effect heterogeneity was observed based on intensive care unit admission reason.
Study context
- Population
- Critically ill patients with acute organ dysfunction, admitted for CV vs non-CV reasons162 CV, 345 non-CV
- Participants
- 507 patients
- Comparison
- Dapagliflozin vs standard care, CV vs non-CV ICU admissions
- Primary endpoint
- Hierarchical composite of:
- Hospital mortality
- Kidney replacement therapy initiation
- ICU length of stay
- Follow-up
- Through 28 days
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
Hierarchical composite of:
- Hospital mortality
- KRT initiation
- ICU length of stay
Win ratio (95% CI)
Cardiovascularcardiovascular subgroup; dapagliflozinvs standard care
0.94(0.77–1.15)
Noncardiovascularnoncardiovascular subgroup; dapagliflozinvs standard care
1.05(0.91–1.21)
Further findings
| Outcome | Difference (mL/day) (95% CrI) | |
|---|---|---|
| Daily parameters in CV patients (Bayesian mixed models)Dapagliflozinvs Standard careUrine output, CrI | 212 (30–392) | |
| Daily parameters in CV patients (Bayesian mixed models)Dapagliflozinvs Standard careFluid balance, CrI | −237 (−447 to −26) | |
| −600−400−2000200400Difference, mL/day (linear scale) |
μg/kg/min
- Daily parameters in CV patients (Bayesian mixed models) — Norepinephrine requirement increase
- 0.01
- Daily parameters in CV patients (Bayesian mixed models) — Dobutamine requirement increase
- 0.43
- Daily parameters in CV patients (Bayesian mixed models): 134 CV patients analysed
- Daily parameters in CV patients (Bayesian mixed models): 95% credible interval
Safety
Serious adverse events
- Similar between arms in both subgroups
Original publication
Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial. JACC Adv. Published 19 December 2025. doi:10. 1016/ j. jacadv. 2025. 102459
Composed by AI from the published abstract and checked against it. How Briefs are made →